Jaypirca showed superior PFS and lower discontinuation rates compared to standard treatments in CLL/SLL patients. Jaypirca reduced the risk of progression or death by 46% to 52% and had a favorable ...

Brukinsa demonstrated superior efficacy and cardiac safety over Imbruvica in CLL/SLL treatment, especially in high-risk patients with 17p deletions. The ALPINE phase 3 trial showed sustained ...

Selected coverage of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, ...

At the American Society of Hematology (ASH) Annual Meeting, held on 6-9 December updated results from the global, multi-centre, open-label, Phase III BRUIN CLL-313 clinical trial were presented. This ...

Please provide your email address to receive an email when new articles are posted on . In the BRUIN CLL-313 trial, researchers compared pirtobrutinib (Jaypirca, Eli Lilly & Co.) vs. bendamustine plus ...

Statin use in CLL/SLL patients treated with ibrutinib reduced cancer-related death risk by 61% and improved survival outcomes. The study found no significant increase in severe side effects with ...

Please provide your email address to receive an email when new articles are posted on . Patients with CLL and SLL who received pirtobrutinib had superior response than those who received ibrutinib in ...

Findings showed pirtobrutinib was noninferior to ibrutinib in both the pre-treated and intent-to-treat populations for the endpoint of ORR. Topline data were announced from a head-to-head phase 3 ...

ORLANDO -- In a phase III trial with potential practice-changing implications, the non-covalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca) induced a higher response rate in ...

Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...

Abbreviations: BR, bendamustine plus rituximab; CLL, chronic lymphocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group performance status; IGHV, immunoglobulin heavy-chain variable region; SLL ...

Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitor This expanded ...